22 related articles for article (PubMed ID: 35177782)
1. TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
da Silva EM; Selenica P; Vahdatinia M; Pareja F; Da Cruz Paula A; Ferrando L; Gazzo AM; Dopeso H; Ross DS; Bakhteri A; Riaz N; Chandarlapaty S; Razavi P; Norton L; Wen HY; Brogi E; Weigelt B; Zhang H; Reis-Filho JS
NPJ Breast Cancer; 2021 Apr; 7(1):43. PubMed ID: 33863915
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients.
Zou C; Huang R; Lin T; Wang Y; Tu J; Zhang L; Wang B; Huang J; Zhao Z; Xie X; Huang G; Wang K; Yin J; Shen J
Front Oncol; 2024; 14():1382276. PubMed ID: 38841159
[TBL] [Abstract][Full Text] [Related]
3. Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications.
Toss A; Piacentini F; Cortesi L; Artuso L; Bernardis I; Parenti S; Tenedini E; Ficarra G; Maiorana A; Iannone A; Omarini C; Moscetti L; Cristofanilli M; Federico M; Tagliafico E
Oncotarget; 2018 Aug; 9(60):31606-31619. PubMed ID: 30167082
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis of human kallikrein 5 (
Song Y; Bai G; Li X; Zhou L; Si Y; Liu X; Deng Y; Shi Y
Cancer Innov; 2023 Oct; 2(5):376-390. PubMed ID: 38090381
[TBL] [Abstract][Full Text] [Related]
5. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
Hu J; Lang R; Zhao W; Jia Y; Tong Z; Shi Y
Breast Cancer Res Treat; 2023 Jul; 200(1):23-36. PubMed ID: 37160814
[TBL] [Abstract][Full Text] [Related]
6. The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer.
Yang Y; Zhang J; Li JY; Xu L; Wang SN; Zhang JQ; Xun Z; Xia Y; Cao JB; Liu Y; Shi LY; Li W; Shi YL; He YG; Gu DJ; Yu ZY; Chen K; Lan J
Gland Surg; 2022 Dec; 11(12):1924-1935. PubMed ID: 36654951
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
Stradella A; Gargallo P; Cejuela M; Petit A; Bosch-Schips J; Carbonell P; Recalde S; Vethencourt A; Fernandez-Ortega A; Falo C; Gil-Gil M; Vázquez S; Obadia V; Villanueva-Vázquez R; Soler-Monsó T; Calabria I; Pernas S
Mod Pathol; 2022 Aug; 35(8):1066-1074. PubMed ID: 35177782
[TBL] [Abstract][Full Text] [Related]
8. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
9. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
10. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Aftimos P; Oliveira M; Irrthum A; Fumagalli D; Sotiriou C; Gal-Yam EN; Robson ME; Ndozeng J; Di Leo A; Ciruelos EM; de Azambuja E; Viale G; Scheepers ED; Curigliano G; Bliss JM; Reis-Filho JS; Colleoni M; Balic M; Cardoso F; Albanell J; Duhem C; Marreaud S; Romagnoli D; Rojas B; Gombos A; Wildiers H; Guerrero-Zotano A; Hall P; Bonetti A; Larsson KF; Degiorgis M; Khodaverdi S; Greil R; Sverrisdóttir Á; Paoli M; Seyll E; Loibl S; Linderholm B; Zoppoli G; Davidson NE; Johannsson OT; Bedard PL; Loi S; Knox S; Cameron DA; Harbeck N; Montoya ML; Brandão M; Vingiani A; Caballero C; Hilbers FS; Yates LR; Benelli M; Venet D; Piccart MJ
Cancer Discov; 2021 Nov; 11(11):2796-2811. PubMed ID: 34183353
[TBL] [Abstract][Full Text] [Related]
11. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
12. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
